Effect of Lactobacillus F19 on the emergence of antibioticresistant microorganisms in the intestinal microflora
|
|
- Hillary Anderson
- 5 years ago
- Views:
Transcription
1 Journal of Antimicrobial Chemotherapy (2004) 54, DOI: /jac/dkh406 Advance Access publication 25 August 2004 Effect of Lactobacillus F19 on the emergence of antibioticresistant microorganisms in the intestinal microflora Åsa Sullivan 1, Anita Johansson 2, Bo Svenungsson 2,3 and Carl Erik Nord 1 * JAC Divisions of 1 Clinical Bacteriology, F82, and 2 Infectious Diseases, Karolinska University Hospital Huddinge, SE Stockholm, Sweden; 3 Division of Infectious Diseases, Karolinska University Hospital Solna, Karolinska Institutet, Stockholm, Sweden Received 16 March 2004; returned 13 June 2004; revised 30 June 2004; accepted 20 July 2004 Objectives: Probiotic lactic-acid-producing bacteria have been used for prevention of gastrointestinal diseases. The aim of the present study was to examine whether Lactobacillus F19 in conjunction with treatment with penicillin, ciprofloxacin or norfloxacin prevents establishment of resistant bacteria in the gastrointestinal tract. Methods: Twenty patients admitted to hospital due for treatment with penicillin and 16 patients due for treatment with ciprofloxacin or norfloxacin were included in the study. In either group, the patients were randomized into two groups, receiving placebo or an active probiotic product. Faecal samples were collected before treatment, on day 10 and 1 month after the start of the treatment. Isolates of enterococci, enterobacteria and Bacteroides fragilis species were screened for resistance to penicillin and ciprofloxacin, respectively. Results: Administration of penicillin did not influence resistance in enterococci while quinolone resistance increased during quinolone treatment. Susceptibility to ampicillin and piperacillin/tazobactam decreased in enterobacteria during penicillin treatment and ciprofloxacin resistance increased in the quinolone group. Penicillin and quinolones did not influence the resistance rates of Bacteroides isolates. No major differences were observed between the probiotic- and placebo-supplemented groups. Conclusions: There was a limited effect of Lactobacillus F19 on the emergence of resistant isolates during treatment with penicillin and quinolones. Keywords: probiotics, resistance, antimicrobial agents Introduction An increasing problem in clinical medicine is the development of bacterial strains resistant to antibacterial agents. Today it is generally accepted that the extensive use of antibiotics is the main reason for the development of the increased bacterial resistance. 1 The human gastrointestinal tract is the natural habitat of microorganisms usually encountered in infections resistant to antimicrobials. The majority of resistant strains are found in patients in hospitals, mainly from patients in intensive care units. 2 Among the aerobic microorganisms, enterococci are regarded as one of the most common causes of nosocomial infection. The majority of enterococcal infections are caused by Enterococcus faecalis followed by Enterococcus faecium. 3 Enterococci are intrinsically resistant to several antibacterial agents, i.e. low-level resistance to cell-wall-active agents and aminoglycosides. 4 However, in the Nordic countries the level of resistance in enterococci is still low. 5 Other aerobic microorganisms frequently encountered among clinical isolates are members of the family Enterobacteriaceae. 6 It has been shown that long-term hospitalized elderly patients are at increased risk of being infected with Gram-negative bacilli resistant to ampicillin. 7 A problem with regard to Enterobacteriaceae, since the introduction of the third-generation cephalosporins, is the increasing number of strains expressing extended-spectrum b-lactamases (ESBLs). Almost 17% of Klebsiella pneumoniae strains in a European multi-centre study were found to be potential carriers of ESBL enzymes. 6 Anaerobic bacteria outnumber aerobic bacteria in the gastrointestinal tract, and among the anaerobic microorganisms, Bacteroides spp. are the most frequent pathogenic bacteria isolated *Corresponding author. Tel: ; Fax: ; carl.erik.nord@labmed.ki.se JAC vol.54 no.4 q The British Society for Antimicrobial Chemotherapy 2004; all rights reserved.
2 Å. Sullivan et al. Clinically important species are the Bacteroides fragilis group. The majority of the B. fragilis group is resistant to penicillins and cephalosporins. Resistance to clindamycin is increasing while resistance to carbapenems and nitroimidazoles is still rare. 8 The gastrointestinal microbial ecosystem is relatively stable but quantitative and qualitative disturbances are seen after oral administration of antibiotics. 9 The normal flora limits the concentration of potentially pathogenic microorganisms, which can reach high numbers in connection with intake of antimicrobial agents. 10 The use of probiotics for prevention of gastrointestinal diseases is well established. 11 However, no studies have been performed on the role of probiotics in the prevention of emergence of resistant isolates. By competition for receptors and nutrition and by production of lactic acid and antimicrobial substances, probiotic strains could be a means by which colonization with resistant strains could be prevented. The aim of the present study was to examine whether administration of Lactobacillus F19 in conjunction with treatment with penicillin or quinolones (ciprofloxacin or norfloxacin) prevents the emergence of resistant isolates of enterococci, enterobacteria and B. fragilis spp. in the intestinal tract. Material and methods Patients Forty-one patients admitted to the Division of Infectious Diseases, Karolinska University Hospital Huddinge, Stockholm, Sweden receiving treatment with penicillin G followed by penicillin V, and 23 patients receiving treatment with ciprofloxacin or norfloxacin were included in the study. None of the patients had any history of gastrointestinal, liver or kidney diseases, and had not been treated with antimicrobial agents within 3 months preceding the study. The two treatment groups were randomized into one placebo and one active group regarding the probiotic supplement in a double-blind fashion. The study was approved by the local ethics committee of Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden. Administration of antimicrobial agents Patients in the penicillin group received penicillin G (Bensylpenicillin; Astra Läkemedel, Södertälje, Sweden) 1 or 3 g three times daily followed by penicillin V (Kåvepenin; Astra Läkemedel) 1 g three times daily and patients in the quinolone group received either ciprofloxacin (Ciproxin; Bayer AB, Göteborg, Sweden) 500 or 750 mg twice per day or norfloxacin (Lexinor; Astra Läkemedel) 400 mg twice daily. Compliance Signed diary cards that were returned at the end of the study checked compliance in respect of the probiotic product. Assay of the probiotic microorganism in faecal samples was a further verification of compliance. Sampling procedures Stool specimens were collected before the administration of antimicrobial agents and probiotic/placebo products (day 1), on day 10 and 30 days after the start of administration. The samples were collected in sterile plastic containers, which were frozen at 708C until processed. Microbiological procedures Stool specimens were suspended in pre-reduced peptone yeast extract medium, diluted to 10 7 and inoculated on the following selective media: Enterococcosel agar (BBL, Cockeysville, MD, USA) for detection of enterococci, CLED agar (Merck, Darmstadt, Germany) for detection of Enterobacteriaceae, BKV (kanamycin vancomycin blood) agar for detection of B. fragilis group, Rogosa agar (Difco, Detroit, MI, USA) for cultivation of lactobacilli and TCCFA agar (Pepton from Casein/Proteose PeptonIII 40 mg/ml, sodium hydrogen phosphate 5 mg/ml, potassium dihydrogen phosphate 1 mg/l, sodium chloride 2 mg/ml, magnesium sulphate 0.2 mg/ml, Bacto agar/agar agar 20 mg/l, taurocholic acid 1 mg/ml, neutral red 0.03 mg/ml, fructose 15%, Clostridium difficile-supplemented D-cycloserine, cefoxitin) for cultivation of C. difficile. Blood agar (LabM Kemila, Bury, UK) was used for total counts of aerobic and anaerobic bacteria. ASM agar (PDM; Biodisk, Solna, Sweden) supplemented with 5% blood and 8 mg/l penicillin G for aerobic microorganisms and 2 mg/l penicillin G for anaerobic microorganisms or ciprofloxacin 4 mg/l (used for aerobic and anaerobic bacteria) was used for assessing the total number of penicillin- or quinolone-resistant microorganisms, respectively. The aerobic agar plates were incubated for 24 h at 378C and the anaerobic plates for 48 h at 378C in anaerobic jars (GasPak; BBL). After incubation different colony types were counted, isolated in pure cultures and identified to genus level. All isolates were analysed according to Gram s stain and colony morphology, followed by biochemical tests. The API 20E kit (biomérieux SA, Marcy l Étoile, France) was used for identification of Enterobacteriaceae. Anaerobic microorganisms were identified to genus level by gas liquid chromatography of metabolites from glucose. The lower limit of detection was 10 2 microorganisms per gram faeces. Isolated strains of C. difficile were tested for cytotoxin production on McCoy cells with an antitoxin kit for detection of toxin B (Tech- Lab, Blacksburg, VA, USA). C. difficile CCUG was used as the reference strain. Administration of probiotic and placebo products The probiotic product consisted of powdered milk (10 g) and colony forming units (cfu) of freeze-dried Lactobacillus paracasei ssp. paracasei F19 (Arla Foods, Stockholm, Sweden). A similar product was given to patients in the placebo groups but with no added microorganisms. The products were prepared in connection with the start of the study and were stored at 708C. After inclusion of a patient, the product was stored at 88C. The products were dissolved in 100 ml water immediately before use. The products were administered twice daily for 14 days. The cell viability was checked after storage under similar conditions. Antibiotic susceptibility tests Up to five colonies of enterococci, Enterobacteriaceae and B. fragilis group spp. were isolated from each patient on each sampling occasion. Depending on which antimicrobial agent had been used as treatment, the MIC of penicillin or ciprofloxacin was determined by the agar dilution method, according to the NCCLS M7-A6 document for aerobic bacteria 12 and the NCCLS M11-A5 document for anaerobic bacteria. 13 Species intrinsically resistant and those found to be resistant on susceptibility testing were further tested for susceptibility to several different antimicrobial agents, i.e. isolates of enterococci were tested against ampicillin, gentamicin, linezolid 792
3 Probiotics and resistance and vancomycin, Enterobacteriaceae were tested against ampicillin, piperacillin/tazobactam, cefotaxime and gentamicin, and B. fragilis group isolates were tested against ampicillin/clavulanic acid, cefoperazone, cefoxitin, imipenem, clindamycin and metronidazole. The control strains used were E. faecalis ATCC 29212, Escherichia coli ATCC 25922, B. fragilis ATCC and Bacteroides thetaiotaomicron ATCC The final inoculum for aerobic bacteria was cfu/spot and for anaerobic bacteria cfu/ spot. Inoculated plates were incubated for 18 h (aerobic bacteria) and 48 h (anaerobic bacteria) at 378C. The breakpoint values used were according to NCCLS recommendations. Detection of ESBLs Isolates of Enterobacteriaceae intermediately resistant or resistant to cefotaxime were tested for production of ESBLs using the Etest (AB Biodisk). K. pneumoniae ATCC and E. coli ATCC were used as positive and negative controls, respectively. Identification of Lactobacillus F19 strains Colony forming units exhibiting colony and Gram s stain morphology similar to the probiotic strain Lactobacillus F19 were analysed by randomly amplified polymorphic DNA-PCR (RAPD-PCR) to verify the identification. The primer Lbc-19 (5 0 -AGTAGCCAC- 3 0 ) was used in screening and OPA-02 (5 0 -TGCCGAGCTC-3 0 ) for identification of Lactobacillus F Statistical analysis The quantitative alterations were compared within groups between pretreatment (day 1) and day 10 and between pretreatment and after treatment (day 30) and were analysed by Wilcoxon s signed rank test for paired samples. The MIC values for each species were compared within groups between pretreatment and day 10 and between pretreatment and day 30 by the Mann Whitney U test in order to detect significant decreases in susceptibility during and after the administration period. Differences in MIC value between the groups were likewise analysed by the Mann Whitney U test. P values <0.05 were considered statistically significant and were adjusted for the multiple analysis. Results Patients: penicillin group Of 41 randomized patients, 20 (49%) completed the study. Seventeen patients were treated for pneumonia and three for streptococcal infections (tonsillitis and erysipelas). The mean age was 59 years (range years), the mean length of hospital stay was 5 days (range 2 11 days), the mean amount of penicillin G was 11 g (range 3 30 g) and the mean total length of antimicrobial treatment (penicillin G followed by penicillin V) was 14 days (range days). There were no statistically significant differences between the patients regarding the above parameters in the active and placebo groups. Twenty-one patients did not complete the study, of whom 13 received new antimicrobial agents, three patients were nauseated by the ingestion of the probiotic/placebo product, four patients felt too ill to be able to complete the study, and in, one case, faecal samples were not received. Patients: quinolone group Of 23 randomized patients, 16 (70%) completed the study. Fourteen patients had urinary tract infections and two patients had fever of unknown origin and cholecystitis. Nine patients were treated with ciprofloxacin 500 mg twice daily and one patient received 750 mg twice daily for 3 days followed by norfloxacin 400 mg twice daily for 14 days and 200 mg twice daily for 14 days. The remaining six patients were treated with norfloxacin 400 mg twice daily. The mean age was 61 years (range years), the mean duration of hospital stay was 4 days (range 2 8 days), and the total length of antimicrobial treatment was 12 days (range 7 31 days) (15 patients <_15 days). There were no statistically significant differences between the patients concerning these parameters in the active and placebo groups. Seven patients did not complete the study. In three cases there was a change of medication or the medication was withdrawn, one patient felt nauseous when drinking the supplement and three subjects failed to produce faecal samples. Compliance Four patients in the penicillin group receiving the active probiotic product returned completed diary cards. In six cases, information was lacking concerning the intake of the probiotic product. In the placebo group, there were six completed diary cards and four incomplete. In the quinolone-treated patients in the active and placebo groups, there were six and seven completed cards and two and one uncompleted cards, respectively. Impact of antimicrobial agents and Lactobacillus F19 on numbers of microorganisms The numbers of enterococci, enterobacteria and Bacteroides species in patients receiving penicillin showed no major changes apart from increased numbers of enterococci in the active group (increase from day 1 to day 30 P < 0.05). The total numbers of penicillin-resistant microorganisms on the penicillin-containing non-selective agar remained stable during the study period. In the patients treated with quinolones, there was a statistically significant increase in the numbers of resistant isolates on the ciprofloxacin-containing non-selective agar (P < 0.05) between day 1 and 10 and numbers of Enterobacteriaceae (P < 0.05) between day 1 and day 30 in the microflora of patients in the placebo group. In the placebo group, the numbers of B. fragilis spp. (P < 0.05), the total number of anaerobic microorganisms (P < 0.001) as well as the total numbers of resistant strains (P < 0.05) increased from day 1 to day 30. No statistically significant changes were seen in the intestinal microflora in the active group. C. difficile was isolated in four samples of four patients treated with quinolones, in one patient on day 10 and in three patients on day 30. Two patients belonged to the placebo and two to the active group. None of these isolates produced toxins. Prevalence of Lactobacillus F19 Lactobacillus F19 was recovered in three samples from 10 patients in the active group of penicillin-treated individuals (log 10 cfu range ) on day 10. In the active group of quinolone-treated patients, Lactobacillus F19 was isolated in three samples of eight patients (log 10 cfu ) on day 10, and one 793
4 Å. Sullivan et al. patient still harboured the probiotic strain on day 30 (log 10 cfu 2.3). Five of the six patients positive for Lactobacillus F19 returned their diary cards completed. In vitro activity of antimicrobial agents against enterococci One isolate from one patient in the active penicillin group was resistant to penicillin, ampicillin and ciprofloxacin on day 10, while the same isolate was sensitive to vancomycin, linezolid and gentamicin. The numbers of ciprofloxacin-resistant enterococci in quinolone-treated patients increased in the placebo group from three of 32 (9%) isolates on day 1 to 21 of 25 (84%) isolates on day 10. Thirty days after the start of treatment, six of 46 (13%) isolates were resistant to ciprofloxacin. In the active group, the corresponding figures were seven of 26 (27%) isolates on day 1, 12 of 20 (60%) isolates on day 10 and 17 of 39 (44%) isolates on day 30. Isolates resistant to ampicillin were detected in one patient in the placebo group and in one patient in the active group in samples from days 10 and 30. Gentamicin-resistant isolates were also detected in all samples from one patient in the active group. All isolates were sensitive to vancomycin and linezolid. In vitro activity of antimicrobial agents against Enterobacteriaceae Before administration of antimicrobial agents, isolates of enterobacteria with decreased susceptibility to ampicillin and piperacillin/tazobactam were detected in patients treated with penicillin (Table 1). The MIC values increased for isolates from sample 2 and decreased again on day 30 in both the placebo and active groups. There was a statistically significant difference between the groups concerning the susceptibility to piperacillin/tazobactam also existing before the start of the study. Exclusion of patients with piperacillin/tazobactam-resistant isolates before treatment revealed the emergence of resistant or intermediately resistant isolates in four patients in the placebo group and one in the active group. In 23 of 135 (17%) isolates in the placebo group, reduced susceptibility to both ampicillin and piperacillin/ tazobactam was observed. The corresponding figure for the active group was nine of 130 (7%) isolates. In both the active and placebo groups, all isolates were susceptible to ciprofloxacin. In the placebo group, four isolates from two patients with decreased susceptibility to cefotaxime were detected on days 10 and 30. Two isolates were intermediately resistant to gentamicin on day 10. Isolates of enterobacteria from patients treated with quinolones were all susceptible to ampicillin and piperacillin/tazobactam. Isolates from one patient in the placebo group and from three patients in the active group were resistant to ciprofloxacin before treatment. All resistant isolates on day 10 were found in samples from these patients. On day 30, resistant isolates were isolated from one additional patient in the placebo group and from two in the active group. Exclusion of patients with resistant isolates before treatment rendered the material too small for statistical analysis. Isolates with reduced susceptibility to cefotaxime and gentamicin were detected in all samples from one patient in the placebo group and from two patients in the active group. Another patient in the active group harboured gentamicin-resistant isolates on day 30. ESBLs One patient treated with penicillin was found to harbour ESBLpositive strains of Klebsiella oxytoca on day 10. The patient belonged to the placebo group. Amongst the quinolone-treated patients, ESBL-positive strains of E. coli was identified in two subjects, one from the placebo and one from the active group. In both cases the strains were found before treatment and on day 10 and in one patient also on day 30. In vitro activity of antimicrobial agents against B. fragilis spp In the penicillin-treated group, isolates of B. fragilis spp. had reduced susceptibility to ampicillin/clavulanic acid, cefoxitin, cefoperazone and clindamycin before, during and after the administration of penicillin (Table 2). There were no Table 1. In vitro activity of antimicrobial agents against isolates of Enterobacteriaceae in 20 patients treated with penicillin and placebo or active probiotic supplement Antimicrobial agent Day of sampling n MIC 50 MIC 90 MIC range S a (%) R a (%) Placebo group ampicillin >128.0 <2.0 > >128.0 >128.0 <2.0 > >128.0 <2.0 > piperacillin/tazobactam 1 50 <4.0/ /4.0 <4.0/ / <4.0/ /4.0 <4.0/4.0 >512.0/ <4.0/ /4.0 <4.0/ / Active group ampicillin >128.0 <2.0 > >128.0 >128.0 <2.0 > >128.0 <2.0 > piperacillin/tazobactam 1 45 <4.0/4.0 <4.0/4.0 <4.0/4.0 < <4.0/ /4.0 <4.0/ / <4.0/4.0 <4.0/4.0 <4.0/ / a S, susceptible; R, resistant; the percentage of intermediately susceptible isolates is not shown. 794
5 Probiotics and resistance Table 2. In vitro activity of antimicrobial agents against isolates of B. fragilis spp. in 20 patients treated with penicillin and placebo or active probiotic supplement Antimicrobial agent Day of sampling n MIC 50 MIC 90 MIC range S a (%) R a (%) Placebo group ampicillin/clavulanic acid / /8.0 <1.0/ / / /8.0 <1.0/0.5 >64.0/ <1.0/ /4.0 <1.0/ / cefoxitin < <4.0 > <4.0 > cefoperazone <4.0 > > > > > clindamycin <0.5 > >0.5 > <0.5 > Active group ampicillin/clavulanic acid 1 50 <1.0/ /4.0 <1.0/ / <1.0/ /4.0 <1.0/ / / /4.0 <1.0/ / cefoxitin < < < cefoperazone <4.0 > >256.0 <4.0 > > clindamycin >32.0 <0.5 > >32.0 <0.5 > <0.5 >32.0 <0.5 > a S, susceptible; R, resistant; the percentage of intermediately susceptible isolates is not shown. differences between the active and placebo groups. Over 90% of all isolates were resistant to penicillin. Two isolates from two patients in the placebo group were resistant to ampicillin/clavulanic acid, cefoxitin, cefoperazone, imipenem and metronidazole on day 10. All other isolates were susceptible to imipenem and metronidazole. Isolates of B. fragilis spp. from quinolone-treated patients showed a similar pattern to that found in the penicillin-treated patients as regards susceptibility to cefoxitin, cefoperazone and clindamycin whilst the majority of isolates were susceptible to ampicillin/clavulanic acid (Table 3). All isolates from one patient in the placebo group had reduced susceptibility to metronidazole (intermediately resistant on days 1 and 30, resistant on day 10). All isolates were susceptible to imipenem. Side effects No adverse events were reported. Eight patients treated with penicillin reported looser stools, four in the active and four in the placebo group. In the quinolone-treated patients there were two individuals who experienced looser stools, one from each of the placebo and active groups. One of the patients also complained of nausea during treatment. Discussion To a minor extent, effects on the normal microflora and development of resistance occurred more in patients treated with penicillin than in quinolone-treated patients. In the penicillintreated group, the impact of treatment on enterococci was seen mainly as increased numbers during the study. However, the numbers before treatment were rather low (median approximately 3.0 log 10 cfu/g faeces in both groups). Penicillin treatment did not affect resistance in enterococci, and in enterobacteria there was an increase in resistance to ampicillin and piperacillin/tazobactam. Approximately 40% of enterobacterial isolates in penicillin-treated patients were resistant to ampicillin before the study. There were differences between patients receiving placebo and active probiotic supplement. There were a few enterobacterial isolates in the placebo group resistant to cefotaxime and gentamicin. The majority of B. fragilis spp. were susceptible to ampicillin/clavulanic acid whilst susceptibility to cefoperazone was generally rather low. Reduced susceptibility to cefoxitin and clindamycin was also observed on all sampling occasions. In the quinolone-treated group the numbers of enterobacteria increased in the placebo group. The increased numbers of enterobacteria partly explain the increase in total numbers of quinolone-resistant aerobic isolates in this group but also reflect the increased numbers of resistant enterococci. Use of fluoroquinolone and length of hospital stay have been shown to be associated with ampicillin resistance in enterococci. 15 Only two patients harboured enterococci resistant to ampicillin and also to ciprofloxacin. Four patients were already colonized with resistant enterobacteria before the treatment. Intake of quinolones during the month preceding admission to hospital has 795
6 Å. Sullivan et al. Table 3. In vitro activity of antimicrobial agents against isolates of B. fragilis spp. in 16 patients treated with quinolones and placebo or active probiotic supplement Antimicrobial agent Day of sampling n MIC 50 MIC 90 MIC range S a (%) R a (%) Placebo group ampicillin/clavulanic acid 1 40 <0.5/ /8.0 <1.0/ / <0.5/ /4.0 <1.0/ / <0.5/ /16.0 <1.0/ / cefoxitin < < <4.0 > cefoperazone <4.0 > <4.0 > >256.0 <4.0 > clindamycin <0.5 > < >0.5 > <0.5 > Active group ampicillin/clavulanic acid 1 34 <1.0/ /2.0 <1.0/ / <1.0/ /2.0 <1.0/ / <1.0/ /2.0 <1.0/ / cefoxitin < < < cefoperazone 1 34 < <4.0 > < < < clindamycin 1 34 < < < < < a S, susceptible; R, resistant; the percentage of intermediately susceptible isolates is not shown. been shown to be a risk factor for the emergence of quinoloneresistant intestinal enterobacteria. 16 Selection of quinoloneresistant E. coli has also been shown to occur after short exposure to quinolones in the intestinal microflora of cancer patients. 17 None of the patients in this study had received antimicrobial agents or been admitted to hospital within the 3 months preceding the study. The resistance rates in B. fragilis group spp. in quinolone-treated patients followed the same pattern as for penicillin-treated patients. The overall difference between placebo and active supplemented groups was rather limited in this study. A plausible explanation could be poor compliance, which is indicated by the low rate of completed diary cards, in particular in the penicillin group. Some patients were old and weak and several subjects complained that they did not enjoy the taste and the consistency of the products. The recovery rate of the probiotic strain was also limited. Lactobacillus F19 was only detected in three of 10 in the penicillin-treated group and in three of eight of the quinolone-treated patients. The antimicrobial agents may also have influenced the probiotic strain: the MICs of penicillin and ciprofloxacin are 0.5 and 1.5 mg/l, respectively. Furthermore, the proportions of the patient groups may have been another factor of importance. The exclusion criteria used restricted the selection, and in particular the quinolone-treated group was rather small. The effect of probiotics is strain dependent and the strain Lactobacillus F19 in combination with Lactobacillus acidophilus and Bifidobacterium lactis has been shown to have a normalizing effect on the microflora of healthy subjects during administration of clindamycin. 18 In that study, which was commenced after the present one, the probiotic was delivered in a fermented milk product that might have been more agreeable to the patients. In conclusion, the effect of Lactobacillus F19 supplement on the emergence of resistance in enterococci, enterobacteria and B. fragilis group during treatment with penicillin or quinolones was limited. References 1. Cristino, J. M. (1999). Correlation between consumption of antimicrobials in humans and development of resistance in bacteria. International Journal of Antimicrobial Agents 12, Elliot, T. S. & Lambert, P. A. (1999). Antibacterial resistance in the intensive care unit: mechanisms and management. British Medical Bulletin 5, European Antimicrobial Resistance Surveillance System (EARSS). Annual Report [Online.] (9 January 2004 date last accessed.) 4. Witte, W. (1999). Antibiotic resistance in Gram-positive bacteria: epidemiological aspects. Journal of Antimicrobial Chemotherapy 44, Suppl. A, Simonsen, G. S., Smabrekke, L., Monnet, D. L. et al. (2003). Prevalence of resistance to ampicillin, gentamicin and vancomycin in Enterococcus faecalis and Enterococcus faecium isolates from clinical 796
7 Probiotics and resistance specimens and use of antimicrobials in five Nordic hospitals. Journal of Antimicrobial Chemotherapy 51, Fluit, A. C., Jones, M. E., Schmitz, F. J. et al. (2000). Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and Clinical Infectious Diseases 30, Leistevuo, T., Toivonen, P., Osterblad, M. et al. (1996). Problem of antimicrobial resistance of fecal aerobic Gram-negative bacilli in the elderly. Antimicrobial Agents and Chemotherapy 40, Fang, H., Edlund, C., Hedberg, M. et al. (2002). New findings in b-lactam and metronidazole resistant Bacteroides fragilis group. International Journal of Antimicrobial Agents 19, Andremont, A. (2003). Commensal flora may play key role in spreading antibiotic resistance. ASM News 69, Vollaard, E. J. & Clasener, H. A. (1994). Colonization resistance. Antimicrobial Agents and Chemotherapy 38, Sullivan, A. & Nord, C. E. (2002). The place of probiotics in human intestinal infections. International Journal of Antimicrobial Agents 20, National Committee for Clinical Laboratory Standards. (2003). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically Sixth Edition: Approved Standard M7-A6. NCCLS, Wayne, PA, USA. 13. National Committee for Clinical Laboratory Standards. (2001). Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria Fifth Edition: Approved Standard M11-A5. NCCLS, Wayne, PA, USA. 14. Björneholm, S., Eklöw, A., Saarela, M. et al. (2002). Enumeration and identification of Lactobacillus paracasei subsp. paracasei F19. Microbial Ecology in Health and Disease Suppl. 3, Torell, E., Cars, O., Olsson-Liljequist, B. et al. (1999). Near absence of vancomycin-resistant enterococci but high carriage rates of quinolone-resistant ampicillin-resistant enterococci among hospitalized patients and nonhospitalized individuals in Sweden. Journal of Clinical Microbiology 37, Richard, P., Delangle, M. H., Raffi, F. et al. (2001). Impact of fluoroquinolone administration on the emergence of fluoroquinoloneresistant Gram-negative bacilli from gastrointestinal flora. Clinical Infectious Diseases 32, Perea, S., Hidalgo, M., Arcediano, A. et al. (1999). Incidence and clinical impact of fluoroquinolone-resistant Escherichia coli in the faecal flora of cancer patients treated with high dose chemotherapy and ciprofloxacin prophylaxis. Journal of Antimicrobial Chemotherapy 44, Sullivan, A., Barkholt, L. & Nord, C. E. (2003). Lactobacillus acidophilus, Bifidobacterium lactis and Lactobacillus F19 prevent antibiotic-associated ecological disturbances of Bacteroides fragilis in the intestine. Journal of Antimicrobial Chemotherapy 52,
Effect of dalbavancin on the normal intestinal microflora
Journal of Antimicrobial Chemotherapy (00), 1 doi:10.109/jac/dkl1 Advance Access publication 1 July 00 Effect of dalbavancin on the normal intestinal microflora Carl Erik Nord*, Gundars Rasmanis and Elisabeth
More informationEcological impact of the des-f(6)-quinolone, BMS , on the normal intestinal microflora C. E. Nord 1, D. A. Gajjar 2 and D. M.
ORIGINAL ARTICLE Ecological impact of the des-f(6)-quinolone, BMS-284756, on the normal intestinal microflora C. E. Nord 1, D. A. Gajjar 2 and D. M. Grasela 2 1 Department of Microbiology, Pathology and
More informationECOLOGICAL IMPACT OF NARROW SPECTRUM ANTIMICROBIAL AGENTS COMPARED TO BROAD SPECTRUM AGENTS ON THE HUMAN INTESTINAL MICROFLORA CARL ERIK NORD
Old Herborn University Seminar Monograph 3: Consequences of antimicrobial therapy for the composition of the microflora of the digestive tract. Editors: Carl Erik Nord, Peter J. Heidt, Volker Rusch, and
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More informationEvaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals
J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationBackground and Plan of Analysis
ENTEROCOCCI Background and Plan of Analysis UR-11 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony count, to perform the identification
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationAntibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting
Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria
More informationMICRONAUT MICRONAUT-S Detection of Resistance Mechanisms. Innovation with Integrity BMD MIC
MICRONAUT Detection of Resistance Mechanisms Innovation with Integrity BMD MIC Automated and Customized Susceptibility Testing For detection of resistance mechanisms and specific resistances of clinical
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationon February 12, 2018 by guest
AAC Accepted Manuscript Posted Online 12 February 2018 Antimicrob. Agents Chemother. doi:10.1128/aac.00047-18 Copyright 2018 Stapert et al. This is an open-access article distributed under the terms of
More informationTest Method Modified Association of Analytical Communities Test Method Modified Germicidal Spray Products as Disinfectants
Study Title Antibacterial Activity and Efficacy of E-Mist Innovations' Electrostatic Sprayer Product with Multiple Disinfectants Method Modified Association of Analytical Communities Method 961.02 Modified
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationEXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING
EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING CHN61: EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING 1.1 Introduction A common mechanism of bacterial resistance to beta-lactam antibiotics is the production
More informationShould we test Clostridium difficile for antimicrobial resistance? by author
Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first
More informationBacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching Hospital, Bengaluru, India
ISSN: 2319-7706 Volume 4 Number 11 (2015) pp. 731-736 http://www.ijcmas.com Original Research Article Bacterial Pathogens in Urinary Tract Infection and Antibiotic Susceptibility Pattern from a Teaching
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationAntimicrobial Resistance in Human Oral and Intestinal Anaerobic Microfloras
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 1993, p. 1665-1669 Vol. 37, No. 8 0066-4804/93/081665-05$02.00/0 Copyright X 1993, American Society for Microbiology Antimicrobial Resistance in Human Oral and
More informationAberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015
Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More informationagainst Clinical Isolates of Gram-Positive Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More informationSecondary peritonitis
Secondary peritonitis Caused by spillage of gastrointestinal microorganisms into the peritoneal cavity secondary to loss of the integrity of the mucosal barriers Etiology: perforation of peptic ulcer traumatic
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationA retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya
A retrospective analysis of urine culture results issued by the microbiology department, Teaching Hospital, Karapitiya LU Edirisinghe 1, D Vidanagama 2 1 Senior Registrar in Medicine, 2 Consultant Microbiologist,
More informationGeneral Approach to Infectious Diseases
General Approach to Infectious Diseases 2 The pharmacotherapy of infectious diseases is unique. To treat most diseases with drugs, we give drugs that have some desired pharmacologic action at some receptor
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationUnderstanding the Hospital Antibiogram
Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital
More informationAn evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage
Journal of Antimicrobial Chemotherapy (1991) 27, Suppl. C, 1-7 An evaluation of the susceptibility patterns of Gram-negative organisms isolated in cancer centres with aminoglycoside usage J. J. Muscato",
More information2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/389/98-FINAL July 1998 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS ENROFLOXACIN (extension to
More information2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose
2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility
More information2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services
2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More information2015 Antimicrobial Susceptibility Report
Gram negative Sepsis Outcome Programme (GNSOP) 2015 Antimicrobial Susceptibility Report Prepared by A/Professor Thomas Gottlieb Concord Hospital Sydney Jan Bell The University of Adelaide Adelaide On behalf
More informationSESSION XVI NEW ANTIBIOTICS
SESSION XVI NEW ANTIBIOTICS New Antibiotics to Treat Anaerobic Infections 2 Goldstein, E.J.C.;* Citron, D.M. Antibiotic Pharmacodynamics 3 Stein, G.E.* Targeting Selenium Metabolism in Stickland Fermentors:
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.
More informationLiofilchem Chromatic Chromogenic culture media for microbial identification and for the screening of antimicrobial resistance mechanisms
Liofilchem Chromatic Chromogenic culture media for microbial identification and for the screening of antimicrobial resistance mechanisms Microbiology Products since 1983 Liofilchem Chromatic ESBL Selective
More informationChristiane Gaudreau* and Huguette Gilbert
Journal of Antimicrobial Chemotherapy (1997) 39, 707 712 JAC Comparison of disc diffusion and agar dilution methods for antibiotic susceptibility testing of Campylobacter jejuni subsp. jejuni and Campylobacter
More informationDetection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran
Letter to the Editor Detection and Quantitation of the Etiologic Agents of Ventilator Associated Pneumonia in Endotracheal Tube Aspirates From Patients in Iran Mohammad Rahbar, PhD; Massoud Hajia, PhD
More informationMercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016
Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate
More informationOriginal Article. Ratri Hortiwakul, M.Sc.*, Pantip Chayakul, M.D.*, Natnicha Ingviya, B.Sc.**
Original Article In Vitro Activity of Cefminox and Other β-lactam Antibiotics Against Clinical Isolates of Extended- Spectrum-β-lactamase-Producing Klebsiella pneumoniae and Escherichia coli Ratri Hortiwakul,
More informationReduce the risk of recurrence Clear bacterial infections fast and thoroughly
Reduce the risk of recurrence Clear bacterial infections fast and thoroughly Clearly advanced 140916_Print-Detailer_Englisch_V2_BAH-05-01-14-003_RZ.indd 1 23.09.14 16:59 In bacterial infections, bacteriological
More informationQuality assurance of antimicrobial susceptibility testing
Quality assurance of antimicrobial susceptibility testing Derek Brown Routine quality control Repeated testing of controls in parallel with tests to ensure that the test system is performing reproducibly
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXVII NUMBER 6 July 2012 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine B. Dowell SM, MLS (ASCP); Sarah K. Parker, MD; James K. Todd, MD Each year the Children s Hospital Colorado
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More information2015 Antibiotic Susceptibility Report
Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
More informationThere are two international organisations that set up guidelines and interpretive breakpoints for bacteriology and susceptibility
ANTIMICROBIAL SUSCEPTIBILITY TESTING ON MILK SAMPLES Method and guidelines There are two international organisations that set up guidelines and interpretive breakpoints for bacteriology and susceptibility
More informationAvailable online at ISSN No:
Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(4): 36-42 Comparative Evaluation of In-Vitro Doripenem Susceptibility with Other
More informationCipro for gram positive cocci in urine
Buscar... Cipro for gram positive cocci in urine 20-6-2017 Pneumonia can be generally defined as an infection of the lung parenchyma, in which consolidation of the affected part and a filling of the alveolar
More information2016 Antibiotic Susceptibility Report
Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates
More informationAntimicrobial Susceptibility Testing: The Basics
Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories
More informationPerformance Information. Vet use only
Performance Information Vet use only Performance of plates read manually was measured in three sites. Each centre tested Enterobacteriaceae, streptococci, staphylococci and pseudomonas-like organisms.
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationQ1. (a) Clostridium difficile is a bacterium that is present in the gut of up to 3% of healthy adults and 66% of healthy infants.
Q1. (a) Clostridium difficile is a bacterium that is present in the gut of up to 3% of healthy adults and 66% of healthy infants. C. difficile rarely causes problems, either in healthy adults or in infants.
More informationESCMID Online Lecture Library. by author
Expert rules in susceptibility testing EUCAST-ESGARS-EPASG Educational Workshop Linz, 16 19 September, 2014 Dr. Rafael Cantón Hospital Universitario Ramón y Cajal SERVICIO DE MICROBIOLOGÍA Y PARASITOLOGÍA
More informationAntimicrobial Update. Alison MacDonald Area Antimicrobial Pharmacist NHS Highland April 2018
Antimicrobial Update Alison MacDonald Area Antimicrobial Pharmacist NHS Highland alisonc.macdonald@nhs.net April 2018 Starter Questions Setting the scene... What if antibiotics were no longer effective?
More informationAnaerobe bakterier og resistens. Ulrik Stenz Justesen Klinisk Mikrobiologisk Afdeling Odense Universitetshospital Odense, Denmark
Anaerobe bakterier og resistens Ulrik Stenz Justesen Klinisk Mikrobiologisk Afdeling Odense Universitetshospital Odense, Denmark Programme anaerobic bacteria Carbapenem and metronidazole resistance New
More informationTowards Rational International Antibiotic Breakpoints: Actions from the European Committee on Antimicrobial Susceptibility Testing (EUCAST)
Towards Rational International Antibiotic Breakpoints: Actions from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) A report to ISC presented by Paul M. Tulkens representative of
More informationESCMID Online Lecture Library. by author
Quality Assurance of antimicrobial susceptibility testing Derek Brown EUCAST Scientific Secretary ESCMID Postgraduate Education Course, Linz, 17 September 2014 Quality Assurance The total process by which
More informationPrevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
More informationPrinciples of Antimicrobial Therapy
Principles of Antimicrobial Therapy Doo Ryeon Chung, MD, PhD Professor of Medicine, Division of Infectious Diseases Director, Infection Control Office SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE CASE 1
More informationEffect of ceftobiprole on the normal human intestinal microflora
Effect of ceftobiprole on the normal human intestinal microflora Tobias Bäckström, Georgios Panagiotidis, Olof Beck, Charlotte Asker-Hagelberg, Mamun-Ur Rashid, Andrej Weintraub, Carl Erik Nord To cite
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More informationEinheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?
Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how? Andrea Duppenthaler andrea.duppenthaler@insel.ch Limping patient local pain swelling tenderness warmth fever acute Osteomyelitis
More informationSummary of the latest data on antibiotic resistance in the European Union
Summary of the latest data on antibiotic resistance in the European Union EARS-Net surveillance data November 2017 For most bacteria reported to the European Antimicrobial Resistance Surveillance Network
More informationComparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria
Comparative Assessment of b-lactamases Produced by Multidrug Resistant Bacteria Juhee Ahn Department of Medical Biomaterials Engineering Kangwon National University October 23, 27 Antibiotic Development
More informationINCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS
INCIDENCE OF BACTERIAL COLONISATION IN HOSPITALISED PATIENTS WITH DRUG-RESISTANT TUBERCULOSIS 1 Research Associate, Drug Utilisation Research Unit, Nelson Mandela University 2 Human Sciences Research Council,
More informationAPPENDIX III - DOUBLE DISK TEST FOR ESBL
Policy # MI\ANTI\04\03\v03 Page 1 of 5 Section: Antimicrobial Susceptibility Testing Manual Subject Title: Appendix III - Double Disk Test for ESBL Issued by: LABORATORY MANAGER Original Date: January
More informationRecommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland
Recommendations for Implementation of Antimicrobial Stewardship Restrictive Interventions in Acute Hospitals in Ireland A report by the Hospital Antimicrobial Stewardship Working Group, a subgroup of the
More informationStanding Orders for the Treatment of Outpatient Peritonitis
Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.
More informationAminoglycosides. Spectrum includes many aerobic Gram-negative and some Gram-positive bacteria.
Aminoglycosides The only bactericidal protein synthesis inhibitors. They bind to the ribosomal 30S subunit. Inhibit initiation of peptide synthesis and cause misreading of the genetic code. Streptomycin
More informationAntibiotic Prophylaxis Update
Antibiotic Prophylaxis Update Choosing Surgical Antimicrobial Prophylaxis Peri-Procedural Administration Surgical Prophylaxis and AMS at Epworth HealthCare Mr Glenn Valoppi Dr Trisha Peel Dr Joseph Doyle
More informationTHE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS
THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be
More informationBacteriology. Mycology. Genova Diagnostics Europe Parkgate House 356 West Barnes Lane New Malden, Surrey. KT3 6NB. Order Number:
Genova Diagnostics Europe Parkgate House 356 West Barnes Lane New Malden, urrey. KT3 6NB Bacteriology Lactobacillus species 3+ Escherichia coli 4+ Bifidobacterium 3+ gamma haemolytic treptococcus NP 4+
More informationMili Rani Saha and Sanya Tahmina Jhora. Department of Microbiology, Sir Salimullah Medical College, Mitford, Dhaka, Bangladesh
Detection of extended spectrum beta-lactamase producing Gram-negative organisms: hospital prevalence and comparison of double disc synergy and E-test methods Mili Rani Saha and Sanya Tahmina Jhora Original
More informationPrevalence of Extended-spectrum β-lactamase Producing Enterobacteriaceae Strains in Latvia
Prevalence of Extended-spectrum β-lactamase Producing Enterobacteriaceae Strains in Latvia Ruta Paberza 1, Solvita Selderiņa 1, Sandra Leja 1, Jelena Storoženko 1, Lilija Lužbinska 1, Aija Žileviča 2*
More informationService Delivery and Safety Department World Health Organization, Headquarters
Service Delivery and Safety Department World Health Organization, Headquarters WHO global (laboratory-based) survey on multidrug-resistant organisms (MDROs) in health care PROJECT SUMMARY Given the important
More informationWhat s new in EUCAST methods?
What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More information2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital
2010 ANTIBIOGRAM University of Alberta Hospital and the Stollery Children s Hospital Medical Microbiology Department of Laboratory Medicine and Pathology Table of Contents Page Introduction..... 2 Antibiogram
More informationInternational Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access.
I J A P B International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access. ISSN: 2454-8375 COMPARISON OF ANTIMICROBIAL ACTIVITY AND MIC OF BRANDED
More informationBactiReg3 Event Notes Module Page(s) 4-9 (TUL) Page 1 of 21
www.wslhpt.org 2601 Agriculture Drive Madison, WI 53718 (800) 462-5261 (608) 265-1111 2015-BactiR Reg3 Shipment Date: September 14, 2015 Questions or comments should be directed to Amanda Weiss at 800-462-5261
More informationVLLM0421c Medical Microbiology I, practical sessions. Protocol to topic J05
Topic J05: Determination of susceptibility of bacteria to antimicrobial drugs, assessments of resistance factors For study: textbooks, www, keywords e. g. Diffusion disc test ; E-test ; dilution micromethod
More information6. STORAGE INSTRUCTIONS
VRESelect 63751 A selective and differential chromogenic medium for the qualitative detection of gastrointestinal colonization of vancomycin-resistant Enterococcus faecium () and vancomycin-resistant Enterococcus
More informationPILOT STUDY OF THE ANTIMICROBIAL SUSCEPTIBILITY OF SHIGELLA IN NEW ZEALAND IN 1996
PILOT STUDY OF THE ANTIMICROBIAL SUSCEPTIBILITY OF SHIGELLA IN NEW ZEALAND IN 996 November 996 by Maggie Brett Antibiotic Reference Laboratory ESR Communicable Disease Centre Porirua CONTENTS Page SUMMARY
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationINFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER
INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are
More information